Skip to main content

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Recruiting · Phase 2, Phase 3 · NCT03373968

Conditions: Duchenne Muscular Dystrophy

At a glance

Research payments reported, 2025
$543,606
U.S. investigators named
9
Sites paid
9
Planned or actual enrollment
206

About the trial

Sponsor
Italfarmaco (with Cromsource)
Tested
Givinostat (drug)
Dates
Started 2017-10-24; completion 2029-12
Results posted
Not yet

This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.

From ClinicalTrials.gov, last updated 2026-01-21. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Itf Therapeutics LLC reported $543,606 in research payments for this study in 2025 (44 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.